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Antibiotic resistance in bacteria is an increasing problem in health care settings worldwide. 
After approximately 70 years of antibiotic use, the bacteria have developed mechanisms that 
let them survive antibiotic treatment. The use of antibiotics is an important factor in resistance 
development. Norwegian dentists prescribe approximately 5.3% of the total antibiotics 
consumed in the country.  
Dentists tend to use mostly β-Lactam antibiotics, metronidazoles, macrolides, lincosamides 
and tetracylines. Bacteria can develop resistance to all kinds of antibiotics, by acquiring 
genetic traits that confer resistance to antibiotics. Horizontal gene transfer is the most 
effective way for bacteria to acquire new genes. Several genes are known to code for 
resistance against several antibiotics. Many of these genes can be found in bacteria residing in 
the oral cavity. 
To ensure rational antibiotic prescribing practices, national guidelines for antibiotic use are 
developed in several countries. The Norwegian ones mention two main indications for the use 
of these drugs in dental practice. These are specified cases of acute odontogenic infections 
and in some forms of periodontitis. The United Kingdom also has guidelines for prescribing 
antibiotic in dental practice, but these contain some differences which are highlighted in this 
review. 
The aim of this paper is to summarize and organize information about antibiotic use and 
antibiotic resistance to better understand the topic and the challenging situation the global 
society faces today; with a special focus on dental practice. An account to simplify and 
explain important terms used in the field of microbiology, essential to understand antibiotic 
resistance, are attempted. The information is mostly gathered from relevant articles published 
at PubMed, mainly consisting of recent publications from the last ten years. Other sources 
used in the current paper are published theses and internet resources from reliable 
organizations, such as WHO and the Norwegian FHI.  
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Antibiotics today are an essential resource in the constant fight against infections. Antibiotics 
are commonly used in food production and human medicine, and in Norway in 2012 there 
was a total consume of about 60 tons, of which about 52 tons in human medicine (1). The 
development of antibiotic resistance, at a rapid pace, is acknowledged by the World Health 
Organization as an international health crisis. In 2015, the World Health Assembly developed 
their Global Action Plan on Antimicrobial Resistance, requesting the global society to act 
united against the situation (2). By the end of 2015, the Norwegian government published 
their National Action Plan against Antibiotic Resistance, with the main goal to reduce the 
antibiotic use by 30% within 2020 (3). Of the total amount of prescribed antibiotics in 
Norway in 2014, dentists prescribed about 5.3 %, which is a slight increase since 2004, but 
more important, there was an increasing prescribing of broad-spectrum antibiotics. The 
government’s action plan proposed that the Norwegian Dental Association took action 
regarding the matter, and the Academic Committee for Recommended Use of Antibiotics in 
Dental Practice was founded (4). Media have, in the last few years, taken more and more 
interest in antibiotic use and overuse, and have highlighted the problem of antibiotic 
resistance to the public. Thus one can say that antibiotic resistance today is a relevant topic of 
discussion in all health disciplines and sectors. 
 
The aim of this paper is to summarize and organize information about antibiotic use and 
antibiotic resistance to better understand the topic and the challenging situation the global 
society faces today; with a special focus on dental practice. An account to simplify and 
explain important terms used in the field of microbiology, essential to understand antibiotic 
resistance, are attempted. The new Norwegian antibiotic prescribing guidelines for dentists 
are compared to the one currently existing in the United Kingdom. The information is mostly 
gathered from relevant articles published at PubMed, mainly consisting of recent publications 
from the last ten years. Other sources used in the current paper are published theses and 
internet resources from reliable organizations, such as WHO and the Norwegian FHI.  
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1.2. Historical background 
There are and have always been bacteria around us, and they are well known to occasionally 
cause different infections in humans and animals. Even though the cause of infection was 
unknown for humans in the old days, they’ve always tried to fight back with different 
remedies (5). The term antibiotic was first used as a noun in 1942, and was described as 
substances produced by microorganisms which are bacteriostatic or bactericidal to other 
microorganisms (6).  Bacteriostatic antibiotics mean antibiotics that inhibit bacterial growth, 
while bactericidal antibiotics mean antibiotics that kill bacteria (7). Synthetic and 
semisynthetic derivatives substances that are designated antimicrobials or microbial agents, 
doesn’t concur with the original antibiotic definition. However, the term antibiotic is still 
used, but nowadays it is extended to apply synthetic produced drugs with antimicrobial 
effects, as well.  
 
Penicillin, as the first antibiotic, was discovered by Sir Alexander Fleming in 1928. It was 
first used to treat humans in the beginning of the 1940’s, and the further development started 
at high rate, in the following years. Nowadays we have several different kinds of antibiotics, 
but the development of new effective ones, has nearly halted. Actually nearly every class of 
antibiotics that we use today was created before the 70’s (5). The combination of an antibiotic 
resistance progress at a higher rate than the development of new antibiotics, has led to the 
problematic situation of antibiotic resistance the world is facing today (2). In total, 22% of the 
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2. The different kinds of antibiotics commonly used in 
dentistry today 
2.1. β-Lactam antibiotics 
	
β-lactam antibiotics is a group of antibiotics containing the β-lactam ring with various side 
chains. Penicillins; members of the β-lactam antibiotics, are the most frequently used 
antimicrobials in dentistry. They target the last step of the peptidoglycan synthesis in the 
bacterial cell wall, which is specific for most bacteria. Cell shape is maintained by peptide 
cross-linked glycan chains, and when the penicillin inhibits this process, the cells lose its 
stability and causes cell lysis. This makes β-lactams antibiotics bactericidal agents (9, 10). 
The penicillins can be divided into main groups according to their different antibacterial 
spectrums. The narrow spectrum penicillin G and penicillin V, as well as the broad-spectrum 
aminopenicillins, are of dental practitioners primary interest.  
 
Penicillin V, phenoxymethylpenicillin, is sufficient acid stable to be orally administered, and 
is effective against most oral gram positive anaerobes and streptococci(11). Penicillin G, 
benzylpenicillin, is acid labile and has to be used intravenous or intramuscular, and thus not 
commonly prescribed in dental practice. The broad spectrum penicillins, the aminopenicillins, 
has a mode of action that is quite similar to phenoxymethylpenicillin, but includes Gram-
negative microbes as well (11). Aminopenicillins is a generic term for ampicillin and 
amoxicillin (12). Their broader spectrum comes from the ability to penetrate the cell wall 
through porins of some gram negative bacteria (11). 
 
Numerous bacteria produce enzymes named β-lactamases, which effectively 
abolish/inactivate the effect of β-lactam antibiotics. The production of β-lactamases account 
for most causes of antibiotic resistance against penicillins. The effect of β-lactamases is 
encountered by β-lactamase inhibitors, which according to the name, inhibits the effect of β-
lactamases by binding and inactivation (11, 13). E.g. clavulanate, sulbactam and tazobactam, 
are all frequently used (13). 
2.2 . Metronidazole 
Metronidazole is a bactericidal drug which is known to be effective against anaerobic bacteria 
in anaerobic conditions (14). It’s known to be the second most used antibiotic by Norwegian 
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dentist (15). It inhibits nucleic acid synthesis, but need to have metabolic activation inside 
cells before it can have any bactericidal effect. The theory is that when the nitro group gets 
reduced inside the anaerobic cell, the reduced products can have cytotoxic effect as inactive 
intermediates. These intermediates are believed to target the organisms RNA, DNA or cellular 
proteins (16). 
2.3 . Macrolides and lincosamides 
Macrolides: is a group of antibiotics that mainly target gram positive cocci, except 
enterococci (17). They are first and foremost bacteriostatic, but they can have a slight 
bactericidal effect as well (18). By binding to ribosomes, they inhibit protein synthesis, and 
do this in two ways. Either it binds to the narrow conduits, nascent peptide exit tunnel, and 
obstruct the passage of nascent peptides on their way out of the ribosome. This inhibits the 
translation in early stages, and prevents bacterial growth (18). The other mode of action is an 
inhibition of selective peptide bond formations between macrolide donors to specific acceptor 
substrates in the bacteria (18). If a patient is allergic to penicillins, the macrolide 
erythromycin may be an alternative antibiotic to use (19). Lincosamides mode of function is 
the same as macrolides, but is quite different in structure (11, 20). Clindamycin is a 
lincosamide and is effective against aerobe and anaerobe species (11). Clindamycin is the 
drug of choice for Norwegian dentists in cases of penicillin-allergy (21).   
 
2.4  Tetracycline 
Tetracycline – a broad spectrum antibiotic that can inhibit both gram positive and gram 
negative bacteria. It inhibits the protein synthesis of bacteria by binding to the ribosomes, 
mainly the 30S subunit, but some also at the 70S. While binding to this subunit, tetracycline 
overlaps an anticodon that is central in proofreading during the mRNA translation. This 
inhibition, leading to incomplete protein synthesis, halts the bacterial development, and is 
therefore a bacteriostatic drug group (11, 22). 
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3. Antibiotic use and guidelines 
3.0.1. Measuring antibiotic consumption 
In order to monitor the use of antimicrobials, there is a need to standardize the measurements, 
so that the gathered data can be reliable and comparable across different countries. One of the 
main challenges would be the variety of drug use on many areas, varying from livestock 
production to different clinical disciplines. Another challenge was that gathered data on drug 
utilization in countries, was in the beginning not comparable on a detailed level, because of 
variety in sources and forms. A central classification system used in systematizing drug 
surveillance is the Anatomical Therapeutic Chemical (ATC) was developed to enable 
methodical data gathering in drug consumption (2, 23). 
 
The ATC system divides drugs into groups at five different levels, according to which organ 
systems they affect and their therapeutic and chemical characteristics. In addition to the ATC-
system, a technical unit called Defined Daily Dose (DDD) was developed. It is a statistical 
unit for antibiotic consumption (15). It’s defined by WHO as: ”The assumed average 
maintenance dose per day for a drug used for its main indication in adults”(24). It does not 
give information about recommended or prescribed daily dose. WHO uses the ATC/DDD-
system as a tool in their antibiotic utilization research and advise other researchers to use the 
same. Keeping to this system facilitates studies of drug consumption over periods of time, and 
between different countries and regions (2, 11, 23, 25). 
3.1. The Norwegian guidelines (2013) for antibiotic use in dental 
health 
In Norway in 2008, “The Antibiotic Centre for Primary Care” made, on request from The 
Norwegian Directorate of Health, the first national guidelines for the use of antibiotics in 
primary care. They were made as a reaction to the worldwide resistance problem, with the 
aim to minimize the development of resistance, by rational antibiotic use in primary health 
care. The guidelines have been updated and renewed once, this happened in 2013. It is made 
as a booklet with more than 300 pages, and this renewed version includes a section for dental 
use of antibiotics, as a separate chapter. This chapter was distributed with Tannlege Tidende, 
reaching every member of the Norwegian Dentist Association counting about 90% of the 
working dentists in the country (26).  
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The guidelines are evidence-based, with aim to maintain low antibiotic use, and more 
importantly, is to keep the use of broad-spectrum antibiotics at a minimum level. The 
guidelines are not legally binding, but it’s said that in general they should be ruling, and in 
cases with bigger deviations, the choice of antibiotics needs a professional well-documented 
justification (27). 
3.1.0. When do we use antibiotics, including types, doses and 
duration  
Generally, there are two main indications where dentists can prescribe antibiotics to treat 
active infections. These are acute odontogenic infections and some cases of marginal 
periodontitis. In acute situations the choice of antibiotic has to be empiric based, and thus the 
choice should be a single drug or combination of two drugs that are likely to succeed. 
Bacterial samples should be taken in cases with evidence of systemic spread, for antibiotic 
sensitivity testing. This is done to gain some time in cases of no clinical effects of empirical 
therapy in the first 24-48 hours. With the antibiotic sensitivity testing results in hand; one can 
change to the right drug immediately, if needed. Dentists in Norway tend to prescribe narrow 
spectrum antibiotics and are generally considered conservative in their prescriptions (15, 27).  
 
3.1.1. Acute odontogenic infections 
Acute odontogenic infections can spread fast and lead to dramatic outcomes. For dental 
practitioners it’s important to know which conditions they normally can treat themselves, and 
which ones they should refer to a hospital. Oral infections are not uncommon in a dentist’s 
workday. Even quite serious cases can be seen and treated relatively easy in primary dental 
care. The oral infections primarily burst from either caries or periodontal diseases, and can 
result in the formation of abscesses, apical and marginal periodontitis, pulpitis, acute 
necrotizing ulcerative gingivitis, necrotizing ulcerative periodontitis and phlegmones. It’s 
when these infections are left untreated; the more severe outcomes may occur, by extending 
from a simple odontogenic tissues into a more serious one and even might cause potentially 
life-threatening infections. In general, most cases of odontogenic infections are effectively 
treated by only incision and drainage (27). Antibiotic therapy should only be prescribed in 
severe cases where systematic development is evident. While awaiting sensitivity test results 
from the lab, empirical antibiotic treatment starts with: 




Phenoxymethylpenicillin: 1 gram, four times a day, for 5 days. 
 
For patients allergic to penicillins, the following regime is recommended; 
Clindamycin: 300mg 4-5 times a day, for 5 days (27). 
3.1.2. Periodontitis 
Periodontitis with all of its forms, from mild to severe, is by some counted as perhaps the 
most common chronic disease in the world (28). It’s an immunologic induced degradation of 
periodontal tissues. The important red complex, Porphyromonas gingivalis, Tannerella 
forsythia and Treponema denticola are the bacterial species identified as significant pathogens 
in most cases of chronic periodontitis in adults (29). Mechanical scaling and root (SRP), with 
or without surgery, is the main treatment of chronic marginal periodontitis. Adequate oral 
hygiene on a daily basis is of course also a main factor, in disease control. But a small, but 
still significant portion, won’t respond to the therapy. For these patients refractory to 
conventional therapy, studies show that antibiotics treatment as supplement to therapy can 
have positive effects on the clinical outcomes (30, 31). It’s important to know that antibiotics 
won’t suffice as a substitute of an inadequate SRP. Before antibiotics are added to the 
treatment, the operator should be satisfied with the patient’s oral hygiene. Next should one 
look at the quality of the SRP, has that been optimal? If those factors are evidently good, a 
bacteria sample should be taken, and sent for laboratory analysis. The answer will determine 
the antibiotic sensitivity of the microbes, and therefore give us the information of what 
antibiotic to use as a supplement to clinical periodontal therapy (27, 30). 
  
For cases of rapidly progressive periodontitis and infections related to P. gingivalis, T. 
forsythia and T. denticola, the following antibiotic regimes are recommended: 
Amoxicillin 250 mg x 3 + Metronidazole 400 mg x 3, each for 5-10 days.  
Or just Metronidazole alone. 
 
For cases of aggressive periodontitis and infections related to Aggregatibacter 
actinomycetemcomitans, the following antibiotic regime is recommended:  
Amoxicillin 250 mg x 3 + Metronidazole 400 mg x 3, each for 5-10 days. 
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For infections related to Enterobacter, for example Escherichia coli, Enterobacter species 
or Klebsiella species, the following antibiotic regime is recommended: 
Ciprofloxacin 250-500 mg for 1-2 weeks. 
 
For patients allergic to penicillins, where penicillin is recommended as a first choice, 
alternative treatment with following regime is recommended: 
Clindamycin: 300mg 4-5 times a day, for 5 days. 
 
3.2. Antibiotic prescribing practices among Norwegian dentists 
A study regarding antibiotic prescriptions by Norwegian dentists, was published in 2007, and 
is based on a questionnaire sent to 10% of randomly selected Norwegian dentists (32). In 
average the dental practitioners prescribed 1.3% antibiotic prescriptions a week. The study 
concluded that Norwegian dental practitioners are conservative in antibiotic prescribing, and 
mainly prescribed the correct type of drugs. But only 3.4 % used laboratory services for 
analysis of bacterial infections, as basis for their prescriptions. It is found a trend of more 
frequently antibiotic prescribing among young dentists and dentists working in northern parts 
of Norway (32). Another study from 2007, based on the total antibiotic prescriptions from 
Norwegian dental practitioners in 2004 and 2005, is probably the first and only one that uses 
the DDD measurement unit system (15, 33). Norwegian dental practitioners prescribed 11 
different antibiotics, which contributed to 8% of the total consumption of those antibiotics in 
Norway. Of the total of 131 128 prescriptions in 2004 phenoxymethylpenicillins amounted to 
75%, metronidazole 6.3%, erythromycin 4.9%, amoxicillin 4.6%, klindamycin 3.7% and the 
last six antibiotics ranging from 2 - 0.08% (15, 33). The narrow-spectrum 
phenoxymethylpenicillin is the first choice of antibiotic in Norwegian dental practice. This 
implies a low prevalence of antibiotic resistance among oral bacteria in Norway (15, 33). In 
2005 and 2006, 73.3% and 70,0% of the working Norwegian dentist issued antibiotic 
prescriptions (15).  
3.3. Guidelines in the UK (UKGL) compared to the Norwegian 
ones (NGL) 
UK got their first guidelines: “Antimicrobial Prescribing for General Dental Practitioners, in 
2006. The second edition was published in 2012, and updated in 2014 (34). The main purpose 
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is described as a tool which can be “useful in decision-making process and to be an aid to 
effective treatment planning and patient care” (35). It’s pointed out that there are just some 
cases where antimicrobials are indicated. Every choice is thoroughly documented with 
reference articles. Dose and dose frequency is stated for adults, and for children as well. They 
have more or less the same indications as in NGL, with acute infections and periodontitis as 
the main classifications. However, in Norway dentists are considered conservative, using the 
narrow-spectrum penicillin phenoxymethylpenicillin, while in the UKGL recommend the 
broad-spectrum penicillin amoxicillin. For the use of antimicrobial therapy in periodontitis 
there are some major differences. In the NGL, it is suggested that bacteria analysis should be 
utilized before prescribing antibiotics, however, in the UKGL it is suggested to refer to a 
specialist, in cases where the patient doesn’t respond to normal treatment. 
 
 
A quite important difference found between the two sets of guidelines regards the choice og 
antibiotics and duration of the treatment. In general, the UKGL recommends metronidazole as 
a first choice for acute odontogenic infections and shorter periods of antibiotic course, for 
example only 3 days regime of metronidazole for different odontogenic infections, whereas 
the NGL recommends 5 days of penicillin V. UKGL does only specify a minimum days of 
treatment when recommending metronidazole, which is the same as treatment durance; 3 
days. When recommending other antibiotic regimes, the UKGL only give the maximum 
period of use, for example in cases of acute dento-alveolar infections where regimes of 
amoxicillin is suggested for up to five days. While the NGL suggests a 5-day regime. It 
should be stressed that not completing an antibiotic course, even though symptoms fades out, 
may lead to bacterial survival and recurrent of infections by mutated resistant bacteria (36).  
 
Another difference that should be pointed out is that only the NGL suggests taking bacterial 
samples for sensitivity analysis. Both guidelines suggest alternatives in cases of patients 










4.0.1. Sources of variation 
An important concept in the field of antibiotics are genetic variations. As the term alludes it is 
genetic changes, which can occur by mutations, rearrangements and gene flow from 
immigration of nearby cell populations (Figure 1). On cell level there are two ways for 
genetic diversity to occur, known as mutations and rearrangements. Mutations are local 
chromosomal DNA sequence changes. Some of them can be highly beneficial for the bacteria, 
due to resistance development, which will be explained later on. Rearrangements are 
structural chromosomal changes, and come in the form of duplications, deletions or 
inversions and translocations. Generally all the rearrangements will be unfavorable or 
destructive, but they sometimes lead to beneficial alterations.  
 
Interaction between cells and population is by far more important in genetic diversity, and 
therefore more in focus in this paper. First and foremost are horizontal gene transfers – 
basically DNA acquisition from nearby cells. Immigration is the concept describing how 
foreign genes spread among populations (37, 38). 
 
 









Another central term in studying the biology of bacterial resistance is the concept of fitness, 
sometimes referred to as Darwinian fitness. Bacterial fitness is the measurement of the ability 
to survive and reproduce for a biological entity (37, 39). With fitness measurements it is 
possible to quantify data and statistically compare certain genotypes performances with other 
genotypes. Fitness commonly divides into absolute fitness and relative fitness. Absolute 
fitness can be described as the total genotypes performance, comprehending survival, 
successful reproduction and fecundity. While relative fitness is typically used for comparing 
bacterial populations (37). There are usually two ways relative fitness is measured; maximum 
exponential growth rate, or mixed competition with start and end ratios. Linked to antibiotic 
resistance, bacterial fitness determines the fate of a mutation. A resistant mutation that causes 
the least fitness cost, is the one that most likely will dominate after ended antibiotic treatment 
(37, 39, 40).   
 
 
4.1. Resistance  
“It is time to close the book on infectious diseases, and declare the war against pestilence 
won”. Which is known as one of the most infamous quotes in the field of microbiology, 
supposedly spoken in 1967, and is credited to the United States Surgeon General, Dr. William 
Stewart. Whether or not he is being correctly quoted (41), the statement is unfortunately 
drastically wrong. Infections remain as one of the main causes for human morbidity and 
mortality in the world, due to the organism’s ability to adapt and adjust to survive antibiotic 
challenges (42). This is known as antibiotic resistance, and makes microbes resistant against 
antimicrobial drugs which originally were effective treatment against the diseases and 
infections caused by it. The problem is aggravated by the massively use and abuse of 
antibiotics, which speeds up the development of resistance rapidly all over the world. 
Bacterial resistance is now reported from all around the world, where diseases and infections 
that used to be easily treated with antibiotics, now will be much harder to treat. Treatment will 
take longer time, requires stronger antibiotics and is considerably more expensive to manage. 
That is if the infections are even possible to treat, especially with the spread of multi drug 
resistance like Methicillin-resistant Staphylococcus aureus (MRSA). In the EU region alone, 
the resistance trouble is estimated to take 25000 humans life a year, with high economic cost 
(11, 36, 43).  
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4.1.1. Natural and acquired resistance 
Antibiotic resistance among bacteria can be either intrinsic [natural] or acquired. Intrinsic or 
innate resistance is basically the ability for the bacteria to naturally withstand antibiotic 
agents, because they either don’t have the structures upon which antibiotics can act on, they 
lack the essential metabolic processes needed for antimicrobial activation, or they have 
mechanisms that expulse the antibiotic before it reach its target (11, 44)  
 
Acquired resistance in bacteria, is traits gained during the lifetime, and happens by genetic 
alteration. There are two different ways for the bacteria to achieve alterations that result in 
antibiotic resistance. It can either do it by chance through mutations in the existing genome, 
that makes it withstand the antibiotic agents, or by receiving already resistant genes from 
other nearby bacteria, a process called horizontal gene transfer (11). 
 
4.2. Horizontal gene transfer (HGT): 
This is by far the most effective way for a bacterial population to acquire resistance genes, 
and HGT is sometimes referred to as bacterial sex. Studies have revealed that approximately 
75% of every bacterium’s genome is a result of horizontal gene transfer throughout the time 
of evolution (37, 45). Bacteria are known to have three common ways to transmit resistant 
genes to other bacteria, named transformation, transduction, and conjugation. There are also 
two other mechanisms, nanotube- and vesicle-mediated gene transfer, but their importance are 
not fully researched yet (37).  
 
4.2.1. Transformation: Is a process were extracellular “naked” DNA segments with 
resistance genes, are taken up by the bacterial cell, from the environment. For this to happen, 
the bacterial cell has to be in a physiological state named competence (46). A competent cell 
can bind naked DNA strands to the cell wall, before uptake across the cell membrane. The 
exogenous DNA has to be similar to the bacterial DNA for incorporation in the genome (a 
process called recombination) (Figure 2). Natural transformation will only occur in bacterial 
cells that naturally competent.(11, 37, 46) 




Figure 2: Transformation: lysis of an antibiotic resistant cell, where a DNA fragment coding for resistance, gets 
picked up by a competent cell and its recombination in the host DNA. 
 
4.2.2. Transduction: Somewhat similar to transformation, but require a virus for 
extracellular DNA transport. Bacteriophages, a bacteria-infecting virus, attach to bacteria and 
releases DNA into the cytoplasm and integrate into the host genome. They may become 
dormant, or they can be triggered to replicate themselves and start lytic growth. Bacterial 
DNA that contains antibiotic resistance gene(s) randomly becomes packed inside 
bacteriophages. The bacteriophages will be released when the host dies, and may attach to a 
new host, releasing its newly adopted resistance gene (Figure 3). Transduction is quite limited 
as a source of gene transfer, because of the host specificity of the bacteriophages. It therefore 
most commonly occurs between highly related bacteria in within the same population (37, 45, 
47). 
 
Figure 3: Transduction: 1. A virulent phage attaches to a bacteria and 2.releases its DNA into the cell, which 
replicates and 3. phage coats are synthesized and randomly pick up hosts resistance gene. 4. the phage carries the 
gene to another host, 4. where it attaches  and 5. releases the gene 6. which gets incorporated in the new hosts 
genome. 
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4.2.3. Conjugation: The most studied form of the HGT (47), and is the transferal of 
mobile genetic elements by cell-to-cell contact, mediated by a conjugative pilus or a pore 
(Figure 4). Conjugation can transfer small DNA fragments and up to large chromosomes 
within species, as well as between some different species. Conjugative genetic elements are 
plasmids and transposons. Depending on the plasmid, some are self-transmissible while 
others are not, and are termed mobilizable. Bacterial cells in dental biofilm show increased 
plasmid spread through conjugation, due to the high density of cells. It is even suggested that 
biofilm construction is stimulated by conjugation. (46-48) 
 
Figure 4: Conjugation process. 1. Donor cell with a conjugative resistant element 2. attaches to recipient nearby 
cell by a pilus and draws it to cell wall contact. 3 the genetic element sends one strand to the other cell, and both 




4.3. Resistance in oral bacteria 
The properties of the oral cavity, with its variety in bacterial habitats, make it a suitable place 
for lots of different bacteria (11). Older articles suggest that there are more than 700 different 
species of microorganisms estimated to be found in the oral cavity, consisting of bacteria, 
fungi, viruses, protozoa and archaea (49).  Newer and more sensitive techniques, which also 
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detect rare species of low concentrations, have identified more than 1000 different bacterial 
species in dental plaque alone (50).  With this high density of bacteria, the possibility of 
bacterial interactions resulting in gene transfer and genetic diversity, are high. Studies have 
shown that HGT is commonly occurring internally in dental biofilm, as well as between 
bacteria passing through the mouth and oral bacteria (46). 
4.3.1. Genes responsible for antibiotic resistance in oral bacteria 
Several genes known to cause antibiotic resistance in bacteria, have been reported to be found 
in bacteria residing in the oral cavity, or recovered from oral infections. Most of these studies 
investigated resistance occurrence in oral bacteria, but are based on cultivable bacterial 
species, and therefore, doesn’t take into account the large numbers of uncultivable bacteria 
present in the oral cavity. Several studies have shown a panel of resistance genes present in 
oral bacteria. These are genes that are responsible of resistance against common antibiotics 
prescribed by dentists. For example, cfxA2, cfxA, bla(TEM) have been reported to be present 
in oral bacteria, which are genes responsible for resistance against β-lactam antibiotics (51-
53). Nim(B) are found in a few studies of periodontal abscesses (54), and it is a gene coding 
for resistance to Metronidazole (55). Erm(B) and erm(F) are genes detected among oral 
bacteria and these genes are associated with resistance against Erythromycin (56, 57). Genes 
coding for tetracycline resistance are known to be common in the oral flora. These genes are 
often found in mobile genetic elements, making them easy to spread. Several tetracycline 
resistance genes are detected among oral bacteria, for example tet(M), tetO, tetQ, tetW (51, 
58, 59). The nucleotide sequence of each gene mentioned herein is listed in the appendix I. 
 
4.3.2.The bacterial resistance mechanisms: 
When bacteria have received new genes that confer antibiotic resistance, it exploits the 
information to protect itself from hostile antibiotic agents. The mechanisms of antibiotic 
resistance are either based on target modification or by reducing the concentration of active 
free antibiotic molecules. On one hand, we have those termed passive mechanisms of 
resistance, meaning those who don’t affect the antibiotic itself, by tampering with the 
pathways the antibiotics uses to reach their target sites. On the other hand, we find those 
termed active mechanisms of resistance, which works directly on the antibiotic agent (42, 60). 
The biochemical mechanisms that the bacteria exhibit for antibiotic resistance can be divided 
into four major groups (figure 5): 




1. Producing an alternative target: normally by producing an enzyme that is resistant to 
the effect of the antibiotic, and keep producing the original sensitive target. The 
original target will be inhibited, while the alternative enzyme “bypasses” the 
antibiotic’s effect and the bacteria survive (61, 62). For example, methicillin resistant 
S. aureus produces an “alternative penicillin binding protein (PBP2a)”, in addition to 
the main target “penicillin binding protein”. PBP2a is not affected by the antibiotic, 
and the bacterial cell continues to function normally (61).  
 
2. Disallowing antibiotics to be in or reach the cytoplasm, either by preventing cell wall 
passage in the first place, by changing the membrane composure making it less 
permeable, or by pumping it out at a higher rate than the entering pace. The latter is 
so-called efflux, and is mediated by energy-requiring efflux-pumps (42, 60, 63, 64). 
For example, tet proteins in E. coli is responsible for tetracycline efflux pumps (60).  
 
3. Changing the antibiotic targets and/or target overproduction. Antibiotic agents that 
actually reaches the target, but is inhibited binding because of alterations in the target 
site structure, while the target still functions properly (42, 60, 63). For example, 
alteration in the penicillin-binding proteins, which lowers the affinity of β-lactam 
antibiotics, or vancomycin targets, by the products of van genes, changes their 
pentapeptide precursor, resulting in a target with lower affinity for vancomycin (63). 
 
4. Antibiotic modification, which is different active ways of directly changing the 
antibiotic agents. Either by enzymatic modifying, by adding chemical groups 
prohibiting target binding. Or bacterial inactivation by enzymes, e.g. β -lactamases, 
which destroys the active component (β -lactam ring) of the penicillin (42, 60, 63).  
 




Figure 5: Depiction of the five different resistance mechanisms mentioned in this paper. Numbers corresponds to 
the paragraph in front of the figure. 
 
4.4. Multidrug resistance 
It is known that bacteria can develop more than one of the abovementioned mechanisms, 
making it even harder to fight. A bacterium that is resistant to two or more antibiotics is 
termed multidrug resistant. The multidrug resistance is known to generate in two different 
ways, ether by receiving several genes, coding for resistance to different antibiotics. For 
example: different plasmids spread through horizontal gene transfer from different bacteria. 
The other way is by increased expression of highly effective efflux pumps, which single-
handedly targets and extrudes several antibiotics – so called multidrug efflux pumps (65, 66).  
4.5. Collateral damage 
As resistance among bacteria is increasing, scientist constantly tries to find new strategies to 
encounter the development of resistance. Recent research has suggested that there is a way to 
make existing antibiotics more efficient, termed collateral sensitivity. The concept was found 
in cancer research, where cancer cell which became resistant to one drug agent, seemed to be 
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more susceptible to other agents. The rationale assumption was that this could affect 
antibiotic resistance as well, especially in patients which are treated with several antibiotics in 
a cycling pattern. In brief, when bacteria have developed resistance to the initial drug, they are 
succeeded by another drug which they now will be more vulnerable to. A big challenge with 
collateral sensitivity is to map the effect of one antibiotic to the sensitivity of the other for a 
given species. When mapping of the E. coli alone, it was laboratory tested against 23 known 
antibiotics, before they could map out the collateral sensitivity network. This sensitivity 
network then can be used as a tool to predict which antibiotic that should be used after each 
other. Needless to say that what works for E. coli will not necessarily work on other species 
(37, 67).   
 
4.6. How to fight antibiotic resistance 
Globally there has been reported increasing numbers of infection-cases where bacterial 
isolates are resistant to all known and available antibiotics. Even though these cases are quite 
few in Norway, it is an increasing problem elsewhere in Europe (1). The spread of resistance 
is acknowledged as a worldwide problem, and it’s agreed upon that there is a need for a 
united worldwide collaboration to encounter the situation. The World Health Assembly 
conducted in 2015, the Global Action Plan on Antimicrobial Resistance, where antibiotic 
resistance is included and addressed in a global scale. As mentioned earlier, use of antibiotics 
is the main driving force for resistance development. Once resistance is originated, it can 
epidemiologically spread through interactions among human beings, between humans and 
animals, through natural environment, water, food, import and travelling (2, 68).  
 
4.6.1. Essential ways to encounter the global progress of antibiotic 
resistance: 
• Reducing the use (2, 15, 27). 
• Information of optimal use (69): for example choose narrow-spectrum antibiotics 
rather than broad-spectrum whenever it is possible (2, 15, 27, 70). 
• Confine the spread of already resistant bacteria by proper infection control measures 
(2). 
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• Surveillance of antibiotic use, globally and international and implementation of 
antibiotic resistance monitoring programes (2, 69). 











































































































































































































































































































Following are the exact nucleotide sequences of antibiotic resistance-causing genes found in 
oral bacteria. They are copied from PubMed Gene bank, and found by the nucleotide-search 





Prevotella denticola strain NI-106 CfxA2-like beta-lactamase (cfxa2) gene, complete cds 
Accession AF504913 
 
ORIGIN   
        1 atggaaaaaa acagaaaaaa acaaatcgta gttttgagta tagctttagt ttgcattttc 
       61 atcttggtat tttcattgtt ccataaatca gcgacaaaag atagcgcaaa tcctccttta 
      121 acaaatgttt tgactgatag catttctcaa attgtctcag cttgtcctgg cgaaattggt 
      181 gtggcggtta ttgttaataa cagagatacg gttaaggtca ataataagag tgtttatcct 
      241 atgatgagtg tgtttaaggt tcatcaggta ttagctcttt gtaatgactt tgacaataaa 
      301 ggaatttcac ttgatacctt agtaaatata aatagggata aacttgaccc taagacttgg 
      361 agtcctatgc tgaaagatta ttcagggcca gtcatatcat tgacagtgag agatttgctg 
      421 cgttatactc ttactcagag tgacaacaat gcaagcaacc ttatgtttaa ggatatggtt 
      481 aatgtcgctc aaacagatag ttttatagcc acactcattc ctcgttcaag ttttcagata 
      541 gcttatacgg aagaggaaat gtcggctgac cataacaagg cttactctaa ctatacatct 
      601 cctcttggtg ctgcaatgtt gatgaatcgt ttgtttactg aaggtcttat cgatgatgag 
      661 aaacaaagtt tcattaagaa tacgttaaaa gaatgcaaaa caggtgtaga taggatagca 
      721 gctccacttc ttgataaaga aggggttgtt atagcgcata agacaggttc aggtgatgtt 
      781 aatgaaaatg gtgttcttgc agctcacaat gatgttgcct atatatgtct gcctaataat 
      841 atcagttata ccttagcggt atttgttaag gatttcaagg gaaatgaatc acaagcgtca 
      901 caatatgttg cgcatatatc agctgtagta tattctttat taatgcaaac ttcagtaaaa 





Citrobacter freundii genes for CFXA, CFXB, complete cds 
Accession AB076667 
ORIGIN   
        1 taattgacgc tatctaatgt catcaagaat ttacttaaca ttctttcaaa atatacttaa 
       61 taaaaatatc aacataccta acacaggtag tattaatgaa taaaaaaata atcatgattt 
      121 tatctgtatt agttttccca ttaacaacat tagctgagag gaccccaaac gaagaaaaaa 
      181 cagttgtagg atatgcagat cataatggtc aattatataa catcacagca atatatggta 
      241 ggactatata ctataacgta ccaaggggaa ctctaacaat taacactacg gatgctactg 
      301 gggcgcgaat acaagtttct tttgattatg cagattatgt tcgagaagcg tttaatgaat 
      361 gggccccggc aggtataagt gtacaagaag ttcctgggcc tggaatggaa gcacgagttg 
      421 tcacattcgg tacatccaat tatgcagata attcattagg cagtacaatc tttgatccgt 
      481 caggaaactc aagattaaga attgacttag gatcatttaa taaaattatt atgaaaaatt 
      541 ttgacaaact caagtctaga aaagcgatcc cagaaaacat gagtcctgag gaatacataa 
      601 aactaaaatt aagaattacc ataaagcatg agatagggca catccttggc ctgttacata 
      661 ataatgaaag tggtgcatac ttcccacatg gtgtcggaca ggaaatagca cgctgtaggc 
      721 tcctgaacca ggctccatcg attatgttaa atggcagtaa ctatgattat atagagcgtt 
      781 tagctcatta tttaggacgg ccggttaccg agtccgatat tggtccttca agaaatgaca 
      841 ttgaaggggt tcgggtaatg agaagaggag gaagttgggg ttcgctaact aatcgatttt 
      901 cctgccttgg tttaggattg gcattttcac gatcaggagg agacctgtaa ttaattatcc 
      961 agcataactt tcaccgactt aaataatatt gtttaggtaa gatatgaaaa ttaaagctta 
     1021 taaaattatg gcctatggtt tcctgatatt gccgctgtat tctaaagcgg cacctcaaaa 
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     1081 tatcacagag ctatgtagtg agtatcataa cactcaaatt tatgaactaa acaaagaaat 
     1141 taagacgtat actgagtctt tagctggcta cagagaaatg gttattattt catttgcaaa 
     1201 tggtgcaaca tttcaggtag aagttcccgg cagtcagcat ttagaatctc aaaagagacc 
     1261 attagagaga atgaaggata cgctaagagc agcatatttc acaggaataa aagtcagcaa 
     1321 gctttgtgtc tggaataata agacaccaaa ttctatcgct gcaatcgaat tgagtaacta 





Kiella pneumoniae plasmid pKP_STM19 beta lactamase TEM (blaTEM) gene, partiallebs 
cds 
Accession JN193524 
ORIGIN               
        1 cattttgcct tcctgttttt gctcacccag aaacgctggt gaaagtaaaa gatgctgaag 
       61 atcagttggg tgcacgagtg ggttacatcg aactggatct caacagcggt aagatccttg 
      121 agagttttcg ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg 
      181 gngcggtatt atcccgtntt gacgccgggc aagagcaact cggtcgccgc atacactatt 
      241 ctcagaatga cttggttgag tactcaccag tcacagaaaa gcatcttacg gatggcatga 
      301 cagtaagaga attatgcagt gctgccataa ccatgagtga taacactgcn gccaacttac 
      361 ttctgacaac gatcggagga ccgaaggagc taaccgcttt tttgcacaac atgggggatc 
      421 atgtaactcg ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc 
      481 gtgacaccac gatgcctgna gcaatggcaa caacgttgcg caaactatta actggcgaac 
      541 tacttactct agcttcccgg caacaattaa tagactggat ggaggcggat aaagttgcag 
      601 gaccacttct gcgctcggcc cttccggctg gctggtttat tgctgataaa tctggagccg 
      661 gtgagcgtgg gtctcgcggt atcattgcag cactggggcc agatggtaag ccctcccgta 
      721 tcgtagttat ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg 









ORIGIN         
        1 gatcatagat gccagttttg tcgttgcccc acgccagcgc aacactcgtg aggagagtgc 
       61 gaagataaag gagggcaagg gcgacgaact gtggaatgac aatcctcaca agaaattcca 
      121 taaggatgtg gatgcccgtt ggacgaagaa gcgcggagac acgttttacg gctacaagca 
      181 gcatgtcaag gtagacaaag gcaacaaggt aatcctctcg tatgcaacaa cgcctgccaa 
      241 tgtgcatgat tccaaaggtt ttgagcagct gcttgatgag tcagacaagg ataaggattt 
      301 gtatcttgac gcaggatatg ccgggcagga gtcaaccgtg aaggagcatg gcatgaatcc 
      361 gataatctgc gagaaaggcc gtcggaatca tcctctgaca gaaaaacaga aggctgagaa 
      421 caggcgcaag tccaagaccc gttgccttgt cgagcacgta ttcggttttg aagagcaaag 
      481 tatgcacggc cttattgtca ggacaatagg gattgtacgg gcaaaggcga atgtggcgat 
      541 gacaaatttg acctacaaca tcttccgcta catccagatt gtgtgcaata aacgtgaatt 
      601 ggcgattgcc caataaaaag agacggggtg tatcctcaaa aatgcaaaaa tccctcattt 
      661 ttttttgggg ggggagatta aattgcttaa ctttacgcaa gattatcttg ctcaagacag 
      721 ttaaagggtt ctgctgtctt atgcaagaaa taaaaaatgg aattgataga acccacctta 
      781 ataacagatt gatatgttta gagaaatgcg acgtaagcgg caattattgc caacagaaga 
      841 aagcgttgcc atccttgaaa ggatgacgaa cggaacattg gctcttcatg gggacgatgg 
      901 ttacccgtat gccgttccca tcagttatgt atatgctgat ggcaaaatat atttccatag 
      961 tgccatgaaa ggtcataaag tggatgccat tttgcagaat gacaaggtat cattctgcgt 
     1021 ggtagaacag gatgacatca gaccgtctga gtttaccact tactttcgaa gtgtgatagt 
     1081 ctttggcaaa gcccacatat tgacggatga actcgaaaaa cgtgttgctt tgggtttatt 
     1141 ggcagacaag tattcgtatg gcgaagctgg catggaggct gaaatagcca aagggttcaa 
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     1201 tcatttgtta atagtgaaaa ttgcaattga gcatattaca ggcaaggaag ccatagaact 
     1261 gaccaaaaat aggaatgacc gtccttgaca ttgcgaccaa cgggaggaca gcaagcggtt 
     1321 ttggtctgcc caaaacacaa acttgctacc attgaaaaac agagttctga cttttgagta 





Lactobacillus salivarius strain CHS-1E ErmB (ermB) gene, partial cds 
Accession HQ651923 
 
ORIGIN         
        1 gtaacgtcta ttgaattaga cagtcatcta ttcaacttat cgtcagaaaa attaaaactg 
       61 aatactcgtg tcactttaat tcaccaagat attctacagt ttcaattccc taacaaacag 
      121 aggtataaaa ttgttgggaa tattccttac catttaagca cacaaattat taaaaaagtg 
      181 gtttttgaaa gccgtgcgtc tgacatctat ctgattgttg aagaaggatt ctacaagcgt 
      241 accttggata ttcaccgaac actagggttg ctcttgcaca ctcaagtctc gattcagcaa 
      301 ttgcttaagc tgccagcgga atgctttcat cctaaaccaa aagtaaacag tgtcttaata 





Bacteroides fragilis partial ermF gene, allele ermFS, strain 3Bac (79a) 
Accession FR692331 
 
ORIGIN         
        1 gacacagctt tggttgaaca tttacgaaaa ttattttctg atgcccgaaa tgttcaagtt 
       61 gtcggttgtg attttaggaa ttttgcagtt ccgaaatttc ctttcaaagt ggtgtcaaat 
      121 attccttatg gcattacttc cgatattttc aaaatcctga tgtttgagag tcttggaaat 
      181 tttctgggag gttccattgt ccttcaatta gaacctacac aaaagttatt ttcgaggaag 
      241 ctttacaatc catataccgt tttctatcat actttttttg atttgaaact tgtctatgag 
      301 gtaggtcctg aaagtttctt gccaccgcca actgtcaaat cagccctgtt aaacattaaa 
      361 agaaaacact tattttttga ttttaagttt aaagccaaat acttagcatt tatttcctgt 
      421 ctgttagaga aacctgattt atctgtaaaa acagctttaa agtcgatttt caggaaaagt 
      481 caggtcaggt caatttcgga aaaattcggt ttaaacctta atgcccaaat tgtttgtttg 




Streptococcus pyogenes strain 2133-99 TetM (tetM) gene, partial cds 
Accession EF363197 
 
ORIGIN         
        1 aaaagtaata tagggattga taaccttata gaagttatta ctaataaatt ttattcatca 
       61 acacatcgag gtccgtctga actttgcgga aatgttttca aaattgaata tacaaaaaaa 
      121 agacaacgtc ttgcatatat acgcctttat agtggagtac tacatttacg agattcggtt 
      181 agagtatcag aaaaagaaaa aataaaagtt acagaaatgt atacttcaat aaatggtgaa 
      241 ttatgtaaga ttgatagagc ttattctgga gaaattgtta ttttgcaaaa tgagtttttg 
      301 aagttaaata gtgttcttgg agatacaaaa ctattgccac agagaaaaaa gattgaaaat 
      361 ccgcaccctc tactacaaac aactgttgaa ccgagtaaac ctgaacagag agaaatgttg 
      421 cttgatgccc ttttggaaat ctcagatagt gatccgcttc tacgatatta cgtggattct 
      481 acgacacatg aaattatact ttctttctta gggaaagtac aaatggaagt gattagtgca 
      541 ctgttgcaag aaaagtatca tgtggagata gaactaaaag agcctacagt catttatatg 
      601 gagagaccgt taaaaaatgc agaatatacc attcacatcg aagtgccg 
(7)	




Enterococcus faecalis strain e291 TetO (tetO) gene, complete cds 
Accession AY660532 
 
ORIGIN         
        1 ggaggaaaat cacatgaaaa taattaactt aggcattctg gctcacgttg acgcaggaaa 
       61 gacaacatta acggaaagtt tattgtatac cagtggtgca attgcagaac tagggagcgt 
      121 agatgaaggc acaacaagga cagatacaat gaatttggag cgtcaaaggg gaatcactat 
      181 ccagacagca gtgacatctt ttcagtggga ggatgtaaaa gtcaacatta tagatacgcc 
      241 aggccatatg gattttttgg cggaagtata ccgttcttta tccgtattag acggagcagt 
      301 attattagtt tctgcaaagg atggcataca ggcacagacc cgtatactgt ttcatgcact 
      361 acagacaatg aagattccga caattttttt catcaataaa attgaccaag aggggattga 
      421 tttgccaatg gtatatcgag aaatgaaagc aaagctttct tcggaaatta tagtgaagca 
      481 aaaggttggg cagcatcccc atataaatgt aacggacaat gacgatatgg aacagtggga 
      541 tgcggtaatt atgggaaacg atgaactatt agagaaatat atgtcaggga aaccgtttaa 
      601 aatgtcagaa ctggaacagg aagaaaacag gagattccaa aacggaacgt tatttcccgt 
      661 ttatcacgga agcgctaaaa acaatctggg gattcggcag cttatagaag tgattgccag 
      721 taaattttat tcatcaacgc ctgaaggtca atctgaacta tgcgggcagg tttttaagat 
      781 tgaatattca gagaaaaggc ggcgttttgt ttatgtgcgt atatatagcg gaacattgca 
      841 tttgagggat gttattagaa tatctgaaaa agagaaaata aaaatcacag agatgtgtgt 
      901 tccgacaaac ggtgaattat attcatccga tacagcctgc tctggtgata ttgtaatttt 
      961 accaaatgat gttttgcagc taaacagtat tttggggaac ggaatactgt tgccgcagag 
     1021 aaaatttatt gaaaatcctc tccctatgct ccaaacaacg attgcagtaa agaaatctga 
     1081 acagcgggaa atattgcttg gggcacttac agaaatttca gatggcgacc ctcttttaaa 
     1141 atattatgtg gatactacaa cgcatgagat tatactttct tttttgggga aagtgcagat 
     1201 ggaagtcatt tgtgccatcc ttgaggaaaa atatcatgtg gaggcagaaa taaaagagcc 
     1261 tactgttata tatatggaaa gaccgcttag aaaagcagaa tataccatcc acatagaagt 
     1321 cccgccaaat cctttctggg cttctgtcgg gttgtccata gagccgctcc ctattggaag 
     1381 cggagtgcag tatgaaagca gagtttcact tggatattta aatcaatcgt tccaaaatgc 
     1441 ggttatggag ggggttcttt atggctgcga gcaggggctg tatggatgga aagtgacaga 
     1501 ctgtaaaatc tgttttgaat atggattgta ttatagtcct gtaagtaccc ccgcagactt 
     1561 tcggctgctt tcccctatcg tattggagca ggctttaaaa aaagcaggga cagaactatt 
     1621 agagccatat ctccactttg aaatttatgc accgcaggaa tatctctcac gggcgtatca 
     1681 tgatgctcca aggtattgtg cagatattgt aagtactcag ataaagaatg acgaggtcat 
     1741 tctgaaagga gaaatccctg ctagatgtat tcaagaatac aggaacgatt taacttattt 
     1801 cacaaatggg cagggagtct gcttgacaga gttaaaagga taccagccag ctattggtaa 
     1861 atttatttgc caaccccgcc gcccgaatag ccgtatagat aaggttcggc atatgttcca 






Prevotella buccalis partial tetQ gene, strain 10Pre (55b) 
Accession FN546888 
 
ORIGIN         
        1 atagagcatg accccaaagg acataaaaga agttttctaa aaataattga cggaagtctg 
       61 agacttcgag acgttgtaag aatcaacgat tcggaaaaat tcatcaagat taaaaatcta 
      121 aaaactatca atcagggcag agagataaat gttgatgaag tgggcgccaa tgatatcgcg 
      181 attgtagagg atatggatga ttttcgaatc ggaaattatt taggtgctga accttgtttg 
      241 attcaaagat tatcgcatca gcatcccgct ctcaaatcct ccgtccggcc agacaggccc 
      301 gaagagagaa gcaaggtgat atccgctctg aatacattgt ggattgaaga cccgtctttg 
      361 tccttttcca taaactcata tagtgatgaa ttggaaatct cgttatatgg tttaacccaa 
      421 aaggaaatca tacagacatt gctggaagaa cgattttccg taaaggtcca ttttgatgag 
      481 atcaagacta tatacaaaga acgacctgta aaaaaggtca ataagattat tcagatcgaa 
      541 gtgccgccca acccttattg ggccacaata gggctgactc ttgaaccctt accgttaggg 
      601 acagggttgc aaatcgaaag tgacatctcc tatggttatc tgaaccattc ttttcaaaat 
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      661 gccgtttttg aagggattcg tatgtcttgc caatccgggt tacatggatg ggaagtgact 





Bifidobacterium longum bv. Longum strain R29 TetW (tetW) gene, partial cds 
Accession DQ988359 
 
ORIGIN         
        1 ggaggtgtac cgctctttgg ctgttttaga tggggccatc ttggtgatct ccgctaaaga 
       61 tggcgtgcag gcccagaccc gtattctgtt ccatgccctg cggaaaatga acattcccac 
      121 cgttatcttt atcaacaaga tcgaccaggc tggcgttgat ttgcagagcg tggttcagtc 
      181 tgttcgggat aagctctccg ccgatattat catcaagcag acggtgtcgc tgtccccgga 
      241 aatagtcctg gaggaaaata ccgacataga agcatgggat gcggtcatcg aaaataacga 
      301 taaattattg gaaaagtata tcgcaggaga accaatcagc cgggaaaaac ttgtgcggga 
      361 ggaacagcgg cgggttcaag acgcctccct gttcccggtc tattatggca gcgccaaaaa 
      421 gggccttggc attcaaccgt tgatggatgc ggtgacaggg ctgttccaac cgattgggga 
      481 acaggggagc gccgccctat gcggcagcgt tttcaaggtg gagtatacag attgcggcca 
      541 gcggcgtgtc tatctacggc tatacagcgg aacgctgcgc ctgcgggata cggtggccct 
      601 ggccgggaga gaaaagctga aaatcacaga gatgcgtatt ccatccaaag gggaaattgt 
      661 tcggacagac accgcttatc cgggtgaaat tgttatcctt cccagcgaca gcgtgaggtt 
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